Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood blood.2024025409.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Simon Mantha, MD MPH, Debra Goldman, MS, Sean M. Devlin, PhD, Ju-Whei Lee, PhD, Diana Zannino, BSc, MSc, Dan Douer, MD, Harry J Iland, MBBS FRACP FRCPA, Mark R. Litzow, MD, Eytan M. Stein, Frederick Appelbaum, MD, Richard A. Larson, Jacob M. Rowe, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 948.

https://doi.org/10.1182/blood.V124.21.948.948

Published: 2014

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.

Pieter R. Cullis, Hagop Kantarjian, Frederick Appelbaum, Susan O’Brien, May Wong, Gavin S. Choy, Steven R. Deitcher

Blood (2007) 110 (11): 1403.

https://doi.org/10.1182/blood.V110.11.1403.1403

Published: 2007

Journal Articles

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, Rudiger Hehlmann

Blood (2006) 108 (6): 1809–1820.

https://doi.org/10.1182/blood-2006-02-005686

Published: 2006

Journal Articles

Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.

Steven M. Kornblau, MD, Deborah E. Banker, MD, Elizabeth Lemker, Zeev Estrov, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Michael Andreeff, MD, PhD, C. Ellen Jackson, Wenjing Chen, Stephen Petersdorf, MD, Elihu Estey, MD, Frederick Appelbaum, MD

Blood (2005) 106 (11): 405.

https://doi.org/10.1182/blood.V106.11.405.405

Published: 2005

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Ian W. Flinn, Kenneth J. Kopecky, M. Kathryn Foucar, David Head, John M. Bennett, Robert Hutchison, William Corbett, Peter Cassileth, Thomas Habermann, Harvey Golomb, Kanti Rai, Elizabeth Eisenhauer, Frederick Appelbaum, Bruce Cheson, Michael R. Grever

Blood (2000) 96 (9): 2981–2986.

https://doi.org/10.1182/blood.V96.9.2981

Published: 2000

Journal Articles

Use of α-2a-Interferon to Treat Cytogenetic Relapse of Chronic Myeloid Leukemia After Marrow Transplantation

Celestia S. Higano, Deborah Chielens, Wendy Raskind, Eileen Bryant, Mary E.D. Flowers, Jerald Radich, Reginald Clift, Frederick Appelbaum

Blood (1997) 90 (7): 2549–2554.

https://doi.org/10.1182/blood.V90.7.2549

Published: 1997

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Use of α-2a-Interferon to Treat Cytogenetic Relapse of Chronic Myeloid Leukemia After Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only